Telix Pharmaceuticals Limited (TLX)

Market Cap	5.63B
Revenue (ttm)	430.80M
Net Income (ttm)	32.82M
Shares Out	334.23M
EPS (ttm)	0.10
PE Ratio	171.80
Forward PE	99.39
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,088
Open	17.12
Previous Close	16.96
Day's Range	16.81 - 17.40
52-Week Range	14.01 - 19.99
Beta	2.38
Analysts	Strong Buy
Price Target	21.00 (+23.38%)
Earnings Date	n/a

About TLX

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis o...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 415
• Stock Exchange: NASDAQ
• Ticker Symbol: TLX
• Website: https://telixpharma.com

Financial Performance

Financial numbers in AUD

Analyst Forecast

According to one analyst, the rating for TLX stock is "Strong Buy" and the 12-month stock price forecast is $21.0.

Price Target

$21.0

(23.38% upside)

Analyst Consensus: Strong Buy